Impact of Growth Hormone Co-Treatment in Patients with Diminished Ovarian Reserve on In-Vitro Fertilisation Outcomes.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP Pub Date : 2025-03-01 DOI:10.29271/jcpsp.2025.03.278

Pinar Karacin, Runa Ozelci, Enes Kumcu, Dilek Kaya Kaplanoglu, Serdar Dilbaz, Yaprak Ustun

{"title":"Impact of Growth Hormone Co-Treatment in Patients with Diminished Ovarian Reserve on In-Vitro Fertilisation Outcomes.","authors":"Pinar Karacin, Runa Ozelci, Enes Kumcu, Dilek Kaya Kaplanoglu, Serdar Dilbaz, Yaprak Ustun","doi":"10.29271/jcpsp.2025.03.278","DOIUrl":null,"url":null,"abstract":"Objective: To assess the efficacy of growth hormone (GH) co-treatment during controlled ovarian stimulation for in-vitro fertilisation (IVF).Study design: Descriptive analytical. Place and Duration of the Study: Department of Gynaecology, Etlik Zubeyde Hanim Training and Research Hospital, Ankara, Turkiye, from January 2010 to 2023.Methodology: A total of 191 women with diminished ovarian reserve (DOR) who underwent IVF cycles were included in the study. Eighty- nine patients with DOR who received GH during the study period were designated as the study group (Group A), and the 102 patients with DOR who did not receive GH were chosen as the control group (Group B). Chi-square and Mann-Whitney U tests were used to compare groups' variables.Results: The Group B's basal estradiol and FSH levels were higher than those of Group A. No significant correlation was found in regards to number of 2PNs (pro-nuclear), and the count of collected oocytes. The clinical pregnancy rate of the groups was comparable [(n = 13 (27.7%) vs. n = 19 (35.2%), p = 0.417)].Conclusion: This study has shown that the clinical pregnancy rate did not increase significantly in the GH group.Key words: Controlled ovarian hyperstimulation, Growth hormone, In-vitro fertilisation, Clinical pregnancy rate.","PeriodicalId":94116,"journal":{"name":"Journal of the College of Physicians and Surgeons--Pakistan : JCPSP","volume":"35 3","pages":"278-281"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the College of Physicians and Surgeons--Pakistan : JCPSP","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29271/jcpsp.2025.03.278","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To assess the efficacy of growth hormone (GH) co-treatment during controlled ovarian stimulation for in-vitro fertilisation (IVF).

Study design: Descriptive analytical. Place and Duration of the Study: Department of Gynaecology, Etlik Zubeyde Hanim Training and Research Hospital, Ankara, Turkiye, from January 2010 to 2023.

Methodology: A total of 191 women with diminished ovarian reserve (DOR) who underwent IVF cycles were included in the study. Eighty- nine patients with DOR who received GH during the study period were designated as the study group (Group A), and the 102 patients with DOR who did not receive GH were chosen as the control group (Group B). Chi-square and Mann-Whitney U tests were used to compare groups' variables.

Results: The Group B's basal estradiol and FSH levels were higher than those of Group A. No significant correlation was found in regards to number of 2PNs (pro-nuclear), and the count of collected oocytes. The clinical pregnancy rate of the groups was comparable [(n = 13 (27.7%) vs. n = 19 (35.2%), p = 0.417)].

Conclusion: This study has shown that the clinical pregnancy rate did not increase significantly in the GH group.

Key words: Controlled ovarian hyperstimulation, Growth hormone, In-vitro fertilisation, Clinical pregnancy rate.

查看原文